DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5337-5343

  Meng, Ling Hua ^a   Kohlhagen, Glenda ^a   Liao, Zhi Yong ^a   Antony, Smitha ^a   Sausville, Edward ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 2,3 FLUOROPHENYL 6,8 DIFLUORO 7 METHYL 4H BENZOPYRAN 4 ONE; APHIDICOLIN; BENZOPYRAN DERIVATIVE; BROXURIDINE; CAMPTOTHECIN; CELL NUCLEUS ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); HISTONE; HISTONE H2AX; NCS 686288; PROTEIN MDM2; PROTEIN P53; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SELECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DNA PROTEIN COMPLEX; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; GENE REPLICATION; HUMAN; HUMAN CELL; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DNA REPLICATION; DNA, NEOPLASM; DNA, SINGLE-STRANDED; DNA-BINDING PROTEINS; FLAVONOIDS; HISTONES; HUMANS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REPLICATION PROTEIN A; S PHASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20444442793     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0003     Document Type: Article

References (33)

1. Akama T, Shida Y, Sugaya T, et al. Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 1996;39:3461-9.
2. Akama T, Ishida H, Shida Y, et al. Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem 1997; 40:1894-900.
3. Akama T, Ishida H, Kimura U, Gomi K, Saito H. Structure-activity relationships of the 7-substituents of 5,4′-diamino-6,8,3′- trifluoroflavone, a potent antitumor agent. J Med Chem 1998;41:2056-67.
4. Loaiza-Perez AI, Kenney S, Boswell J, et al. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1. J Urol 2004;171:1688-97.
5. Kuffel MJ, Schroeder JC, Pobst LJ, et al. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 2002;62:143-53.
6. Loaiza-Perez AI, Kenney S, Boswell J, et al. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004;3:715-25.
7. Bertrand R, Pommier Y. Assessment of DNA damage in mammalian cells by DNA filtration methods, in cell growth and apoptosis: a practical approach. Oxford: IRL Press, Oxford University Press; 1995. p. 96-117.
8. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13.
9. Sordet O, Khan QA, Pommier Y. Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction. Cell Cycle 2004;3:1095-7.
10. Antony S, Jayaraman M, Laco G, et al. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res 2003;63:7428-35.
11. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003; 278:20303-12.
12. 1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 2004;64:9086-92.
13. Shao RG, Cao CX, Zhang H, et al. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J 1999;18:1397-406.
14. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
15. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22.
16. Pommier Y, Redon C, Rao A, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173-203.
17. Meng L-H, Liao Z-H, Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr Top Med Chem 2003;3:305-20.
18. Redon C, Pilch D, Rogakou E, et al. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002; 12:162-9.
19. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273: 5858-68.
20. Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol 2001;11:R229-32.
21. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A 1985;82:3262-6.
22. Feijoo C, Hall-Jackson C, Wu R, et al. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001;154: 913-23.
23. Oakley GG, Loberg LI, Yao J, et al. UV-induced hyperphosphorylation of replication protein A depends on DNA replication and expression of ATM protein. Mol Biol Cell 2001;12:1199-213.
24. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
25. Kohn KW, Pommier Y, Kerrigan D, Markovits J, Covey JM. Topoisomerase II as a target of anticancer drug action in mammalian cells. NCI Monogr 1987;4:61-71.
26. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
27. Kohn KW. Beyond DNA cross-linking: history and prospects of DNA-targeted cancer treatment: fifteenth Bruce F. Cain memorial award lecture. Cancer Res 1996; 56:5533-46.
28. Connelly JC, Leach DR. Repair of DNA covalently linked to protein. Mol Cell 2004;13:307-16.
29. Subramanian D, Kraut E, Staubus A, Young DC, Muller MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55: 2097-103.
30. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J Biol Chem 2001;276:47759-62.
31. Robison JG, Elliott J, Dixon K, Oakley GG. Replication protein A and the Mre11.Rad50.Nbs1 complex co-localize and interact at sites of stalled replication forks. J Biol Chem 2004;279:34802-10.
32. Dart DA, Adams KE, Akerman I, Lakin ND. Recruitment of the cell cycle checkpoint kinase ATR to chromatin during S-phase. J Biol Chem 2004;279: 16433-40.
33. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003;1:1017-26.